Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …

When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …

Highlights•This clinical practice guideline provides key recommendations on the
management of gastrointestinal stromal tumours.•Recommendations have been agreed …

Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted
incidence of around 1/100 000/year [1]. This only covers clinically relevant GISTs, since, if …

Background Until now, only imatinib and sunitinib have proven clinical benefit in patients
with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually …

Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in the
gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in …

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers.
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …

Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-
free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared …

Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of
personalized treatment for cancer patients. The nearly simultaneous discovery of a …

PURPOSE Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for
advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch …